PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer

PURPOSE: Poly(ADP-ribose) polymerase inhibitors (PARPi) have changed the management of high-grade serous ovarian cancer (HGSOC). The rationale for the development of PARPi was based on the concept of synthetic lethality, in which a cell can survive a deficiency of one gene/gene product, but may die...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Robert D., Clamp, Andrew R., Evans, D. Gareth R., Edmondson, Richard J., Jayson, Gordon C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854713/
https://www.ncbi.nlm.nih.gov/pubmed/29464354
http://dx.doi.org/10.1007/s00280-018-3532-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854713/
https://www.ncbi.nlm.nih.gov/pubmed/29464354
http://dx.doi.org/10.1007/s00280-018-3532-9

Ejemplares similares